Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mean difference between treatment groups in the change from baseline for all PRO scores at months 1, 2 and 3. *Evaluable patients. Mean difference between.

Published byBritt Pålsson Modified over 5 years ago

Similar presentations

Presentation on theme: "Mean difference between treatment groups in the change from baseline for all PRO scores at months 1, 2 and 3. *Evaluable patients. Mean difference between."— Presentation transcript:

1 Mean difference between treatment groups in the change from baseline for all PRO scores at months 1, 2 and 3. *Evaluable patients. Mean difference between treatment groups in the change from baseline for all PRO scores at months 1, 2 and 3. *Evaluable patients. Interpretation of the PRO scales: for FACT-Cog higher scores are favourable; for EORTC QLQ-C30 functional scales and global health status/QoL higher scores are favourable, for EORTC QLQ-C30 symptom scales lower scores are favourable; for BPI-SF and BFI-SF lower scores are favourable. AAP, abiraterone acetate plus prednisone; BFI-SF, Brief Fatigue Inventory-Short Form; BPI-SF, Brief Pain Inventory-Short Form; ENZ, enzalutamide; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life questionnaire; FACT-Cog, Functional Assessment of Cancer Therapy -Cognitive Function; PRO, patient-reported outcome; QoL, quality of life. Antoine Thiery-Vuillemin et al. ESMO Open 2018;3:e000397 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Mean difference between treatment groups in the change from baseline for all PRO scores at months 1, 2 and 3. *Evaluable patients. Mean difference between."

Similar presentations

A Survey of Quality of Life Following Surgery for Malignant Pleural Mesothelioma: Reflects the patients’ commitment to Learning about the Disease D A Raffle,

A Survey of Quality of Life Following Surgery for Malignant Pleural Mesothelioma: Reflects the patients’ commitment to Learning about the Disease D A Raffle,
Date of download: 6/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Randomized Trial to Evaluate the Efficacy of Cognitive.

Date of download: 6/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Randomized Trial to Evaluate the Efficacy of Cognitive.
Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.
LUX-Lung 3 clinical trial

LUX-Lung 3 clinical trial
An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With.

An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With.
Stephanie J. Lee, Loretta A. Williams 

Stephanie J. Lee, Loretta A. Williams 
Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.
A Multitargeted Treatment Approach for Anemia and Cachexia in Metastatic Castration- Resistant Prostate Cancer  Antonio Macciò, MD  Journal of Pain and.

A Multitargeted Treatment Approach for Anemia and Cachexia in Metastatic Castration- Resistant Prostate Cancer  Antonio Macciò, MD  Journal of Pain and.
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera.

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera.
Quality-of-life scores in neurogenic thoracic outlet syndrome patients undergoing first rib resection and scalenectomy  Danielle H. Rochlin, BA, Marta.

Quality-of-life scores in neurogenic thoracic outlet syndrome patients undergoing first rib resection and scalenectomy  Danielle H. Rochlin, BA, Marta.
Capture, Transfer, and Feedback of Patient-Centered Outcomes Data in Palliative Care Populations: Does It Make a Difference? A Systematic Review  Simon.

Capture, Transfer, and Feedback of Patient-Centered Outcomes Data in Palliative Care Populations: Does It Make a Difference? A Systematic Review  Simon.
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
Evaluating Cognitive, Emotional, and Physical Fatigue Domains in Daily Practice by Single-Item Questions in Patients With Advanced Cancer: A Cross-Sectional.

Evaluating Cognitive, Emotional, and Physical Fatigue Domains in Daily Practice by Single-Item Questions in Patients With Advanced Cancer: A Cross-Sectional.
Stacy D. Sanford, PhD, Jennifer L

Stacy D. Sanford, PhD, Jennifer L
Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.
Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Similar presentations

Ads by Google